GlaxoSmithKline (GSK), the UK's largest drugmaker, has acquired Swiss-based GlycoVaxyn, a privately held specialist vaccine biopharmaceutical producer, from Edmond de Rothschild Investment Partners in an all-cash transaction valuing the vaccine maker at about $212 million.
Recently, Codexis has signed a platform technology license agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, granted GSK a license to use the company's proprietary CodeEvolver protein engineering platform technology in the field of human healthcare.
GlaxoSmithkline (GSK), the UK's largest pharmaceutical producer, will pay the Chinese government nearly $500 million in fines after being found guilty of offering bribes to healthcare workers.
Acknowledging that its local management had broken the law and also violated company rules, GSK has apologized to Chinese patients, doctors and hospitals and to the Chinese government.
An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into clinical trials with human patients, and the company plans to immediately begin building a stockpile of up to 10,000 doses for emergency deployment if results are good.
Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, announced that Gordon Sangster has agreed to join Codexis as Senior Vice President & Chief Financial Officer. Gordon, who will start on August 18, 2014, will manage all aspects of Codexis' financial and accounting functions and will report to John Nicols, President & Chief Executive Officer.
Allegations of corruption continue to dog British pharmaceutical company GlaxoSmithKline (GSK).
The latest reports come from Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by the news agency Reuters.
Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries headquartered in Redwood City, Calif./USA, has signed a platform technology license agreement with GlaxoSmithKline (GSK).
Prosecutors in Shanghai have indicted Peter Humphrey, a 58-year-old UK citizen, and Yu Yingzeng, a 61-year-old US citizen, for illegally obtaining personal information on Chinese citizens, the official Chinese news agency Xinhua reports.
It is the first indictment Chinese prosecutors have announced of foreigners for conducting an illegal investigation, according to Xinhua.
The agency said local courts will hear the case of the two investigators at an unspecified date.
GlaxoSmithKline (GSK) has confirmed the existence of an intimate video recording of its former China head, Mark Reilly, which the London-based Sunday Times reported kicked off a bribery investigation that has damaged the pharmaceutical giant's business in China.
The newspaper said the recording was shot without Reilly's knowledge or consent at his Shanghai flat and showed the Briton, who is separated from his wife, with his Chinese girlfriend.
UK pharmaceutical producer GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, news agencies report, citing people familiar with the matter.